Infographic: ‘American Diabetes Association 2013’ – The impact on key drugs...
By Sebastian Heinzmann, Analyst
25 June 2013
I am an Analyst for cardiovascular and metabolic diseases at Datamonitor Healthcare, focusing primarily on the diabetes ...
Read full bio
As Chicago’s annual gathering of the American Diabetes Association draws to a close, use our infographic to quickly visualize the impact of study results on key drugs.
Compare the conference outcome for a number of new market entrants and leading pipeline treatments, including Eli Lilly‘s experimental drug dulaglutide and Sanofi’s investigational new insulin U300, with the following insight:
- Perception Shift Score based on expert Analyst opinion
- Historic vs. Projected Revenue comparing 2012 and 2023 performance
- Drug Summaries based on highlights of presentation data
Download your free infographic using the adjacent form.
For any questions regarding this infographic, or our diabetes analysis in general, please contact our team.